Lonsurf is approved by FDA for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma

Lonsurf

Share This Post

Trifluridine/tipiracil tablets (LONSURF, Taiho Pharmaceutical Co., Ltd.) were approved by the Food and Drug Administration on February 22, 2019 for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior line adenocarcinomas, a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor

TAGS (NCT02500043), an international, randomized, double-blind, placebo-controlled trial, was accepted in 507 patients with metastatic gastric or GEJ adenocarcinoma who had previously undergone at least two previous chemotherapy lines of care. Patients were randomized 2:1 to receive Lonsurf (n=337) 35 mg/m2 orally twice daily on Days 1-5 and 8-12 of each 28-day cycle with best supportive care (BSC) or matching placebo (n=170) with BSC until disease progression or unacceptable toxicity.

The median average survival for patients treated with Lonsurf was 5.7 months (4.8, 6.2) and 3.6 months (3.1, 4.1) for those treated with placebo (hazard ratio: 0.69; 95% CI: 0.56, 0.85; p=0.0006). In patients randomized to the Lonsurf arm (hazard ratio 0.56; 95 percent CI: 0.46, 0.68; p<0.0001), progression-free survival was also longer.

In the TAGS report, neutropenia, anemia, nausea, reduced appetite, thrombocytopenia, vomiting and diarrhea were the most common adverse reactions or laboratory anomalies (approximately 10% incidence) in patients treated with Lonsurf, occurring at a higher rate than in patients treated with placebo.

The prescribed dosage and schedule for Lonsurf is 35 mg/m2/dose orally twice daily with food for each 28-day period on Days 1 through 5 and Days 8 through 12.

View full prescribing information for LONSURF.

FDA granted this application priority review and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
CAR T-Cell therapy

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

CAR T cell therapy has transformed cancer treatment, especially in hematological malignancies. Treatment of solid tumors remains challenging due to their immunosuppressive tumor microenvironment. Combination with chemotherapy, immune checkpoint inhibitors, oncolytic viruses, and improved genetic engineering holds promise. Multimodal approaches enhance immune cell infiltration and persistence, raising efficacy. Evolving personalized methods will be instrumental in overcoming solid tumor resistance and improving patient outcomes.

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
CAR T-Cell therapy

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies?

CAR T-cell therapy revolutionized cancer therapy, offering incredible success in the management of B-cell malignancies, but it is associated with severe infection risks secondary to immunosuppression. Preventive measures are pre-infusion screening, vaccination, and antimicrobial prophylaxis. Post-infusion, close surveillance for infection and cytokine release syndrome management are key. Long-term care includes the treatment of hypogammaglobulinemia, revaccination, and patient education. The approach ensures improved outcomes and reduces infection-related complications in patients receiving CD19-targeted CAR T-cell therapy.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟